Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 6/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.74 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074619 | 1.00 | PDGFRB (0.74) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL6033532 | 0.93 | PDGFRB (0.74) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL4299023 | 0.85 | PDGFRB (1.00) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL29357672 | 0.84 | PDGFRB (0.96) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL244602 | 0.81 | PDGFRB (0.77) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL20216792 | 0.79 | PDGFRB (0.74) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL6608733 | 0.79 | PDGFRB (0.74) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL16346602 | 0.79 | PDGFRB (0.74) | PDGFRBPDGFRATLR8ALDH1A1NPC1 | |
| SCHEMBL5833750 | 0.79 | NPC1 (0.54) | PDGFRBPDGFRAALDH1A1NPC1RAB9A | |
| SCHEMBL1059698 | 0.77 | PDGFRB (0.77) | PDGFRBPDGFRATLR8ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111164083-B | Novel ALK2 inhibitors and methods for inhibiting BMP signaling | 布里格姆妇女医院股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| WO-2010015680-A1 | FUNGICIDE OXYALKYLAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | PDGFRB 4750/4885PDGFRA 4741/4885TLR8 947/4885 |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | PDGFRB 59/4885PDGFRA 46/4885TLR8 1134/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | PDGFRB 4785/4885PDGFRA 4737/4885TLR8 723/4885 |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | PDGFRB 57/4885PDGFRA 75/4885TLR8 1066/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | PDGFRB 4785/4885PDGFRA 4737/4885TLR8 723/4885 |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | PDGFRB 57/4885PDGFRA 75/4885TLR8 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.